Posted on

Pure Extracts Signs White Label Agreement With West Coast Licensed Producer

Pure Extracts Signs White Label Agreement With West Coast Licensed Producer

Vancouver, B.C., January 12, 2022 – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has signed a custom manufacturing/white label agreement with a West Coast Licensed Producer to launch a line of vape products.

The agreement calls for the extraction of premium cannabis supplied by the LP and the subsequent formulation into high quality, full-spectrum oil (FSO) 1 gram vape cartridges. These products will be created by collaboration between the two companies with a reliance on Pure Extracts’ 30+ proprietary formulations and its optimized vape hardware. Pure Extracts will be providing co-manufacturing extraction services. The initial order has an approximate retail sales value of $525,000

This science-based LP has extensive experience in the growing medical-grade cannabis for patients and are now excited to apply their experience towards producing first-rate cannabis for the legalized adult-use market in Canada. Their meticulous standards are used at every step of product development, from growing and processing to R&D.

Pure Extracts CEO, Ben Nikolaevsky, remarked, “We are excited about launching a white label product with our new customer, as they are focused on creating state-of-the-art products utilizing cannabis they grow themselves. With the addition of this customer and the increased capacity and flexibility our new cosolvent injection system provides, we have begun to execute our strategy with high quality producers and branding specialists to get their white label products into the provincial retailers and drive up to $3 million of annual revenue from this vertical.”

ON BEHALF OF THE BOARD

“Ben Nikolaevsky”
Ben Nikolaevsky
CEO and Director

About Pure Extracts (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ)

Pure Extracts Technology Corp. features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020, and its Sales Amendment on July 19, 2021. The Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020.

Find out more at https://pureextractscorp.com/

Or contact:

Pure Extracts Investor Relations
Tel: +1 604 493 2052
info@pureextractscorp.com    

This news release contains forward-looking statements relating to the future operations of Pure Extracts,

and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. A number of factors could cause actual events, performance or results to differ materially from what is projected in forward looking statements. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under “Risk Factors” in the Company’s Annual Information Form. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

This news release contains information about potential sales revenue from supply agreements, which may be considered as disclosure of financial outlook under applicable securities laws. Such information is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraph. Specifically, estimated sales revenue which may be derived from supply contracts has been calculated based on current wholesale prices and assume, among other things, that the Company will be able to find buyers for its products. The financial outlook contained in this news release was made by management as of the date of this news release and was provided for the purpose of providing readers with an understanding of the potential revenue which may be derived from any agreements recently entered into by the Company, and are not an estimate of profitability or any other measure of financial performance. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

The CSE has neither approved nor disapproved the contents of this press release.

Posted on

Wesana Health Provides Strategic and Operational Updates

Wesana Health Provides Strategic and Operational Updates

  • Wesana granted pre-IND meeting with FDA, currently set for March 11, 2022
  • Wesana Clinics exhibited a record quarter of billings, new patient visits, telemedicine utilization, overall patient appointments, and ketamine administrations
  • New flagship clinic set to open in late Q1 2022 showcasing the service evolution of Wesana Clinics
  • Strategic restructuring program to realize $1.1M in general corporate overhead reduction and improve operational efficiencies

CHICAGO and TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc.  (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce the following strategic and operational updates to the Company’s Care Development and Care Delivery businesses in addition to leadership changes as the Company streamlines its strategy going into FY 2022.

Care Development

Program overview

Wesana’s drug development program looks to utilize combination therapy to treat the symptoms associated with Traumatic Brain Injury (“TBI”), such as depression and anxiety, and migraines. By utilizing psilocybin and cannabidiol (“CBD”), a combination therapy of compounds with demonstrated effectiveness, Wesana’s lead drug candidate, SANA-013, is targeted to improve neuroplasticity and neurogenesis while acting as an anti-neuroinflammatory. In contrast to therapist assisted, single dose therapy, where a large dose of psilocybin is administered in clinic, which has exhibited poor durability and waning effects over a short time-period, SANA-013 utilizes a loading dose of psilocybin in combination with self-administered at-home maintenance doses of psilocybin and CBD to provide more sustained effects and benefit over time.

Pre-IND meeting milestone

The U.S Food and Drug Administration (“FDA”) granted the Company’s request for a pre-Investigational New Drug (“IND”) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of TBI-related major depressive disorder (“MDD”).

In the pre-IND meeting, scheduled for March 11, the Company expects to receive feedback from the FDA on its toxicology program and research to-date. The outcome of the meeting will provide key development guidance in advance of IND clearance and initiation of the Phase I clinical trial, currently anticipated to occur in late 2022.

Mark Wingertzahn, Chief Scientific Officer of Wesana commented: “We are impressed with the latest Wesana data and look forward to discussing our drug development approach with regulators in the US and abroad.”

Care Delivery

Record Q4 numbers at Wesana Clinics

The Company is pleased to report that following its previously announced milestone of 4,000 ketamine infusions since the clinic’s inception, Wesana Clinics (the “Clinics”) have shown tremendous growth. The Clinics realized a record quarter in Q4 of billings, new patient visits, telemedicine utilization, overall patient appointments, and ketamine administrations. The record quarter can be attributed to an increase in marketing efforts inclusive of relationship building with the provider and therapist community and strategic and targeted marketing communications.

Wesana Clinics saw a 40% increase in new patient volume and a 29% increase in new appointments relative to the previous quarter. In December 2021, compared to the prior month, Ketamine infusions have also exceeded previous records by 52% while Spravato appointments have increased by 35%. Additionally, the Clinics are expanding access to mental health care through higher utilization of telemedicine appointments. Telemedicine appointments accounted for 57% of all appointments in the last quarter.

Dr. Abid Nazeer, Wesana’s Chief Medical Officer, commented: “I am incredibly pleased with the growth and optimization of the clinics since Wesana’s acquisition in September. Even taking into consideration the backdrop of increasing COVID-19 cases in Chicago, our ability to achieve record numbers is evidence that there is a growing need for accessible, effective, and patient-focused quality mental health care models that integrate established treatment approaches with novel care paradigms. Wesana’s expertise in marketing combined with our existing success in operations has created a winning combination for our patients and improved operating leverage for shareholders.”

Clinic Expansion within Chicago

The Company is also pleased to announce the expansion of clinical operations through the build-out of a third clinic in Naperville, Illinois. Strategically located approximately 25 minutes from the company’s clinic in Oak Brook, IL and 45 minutes from the clinic in downtown Chicago, the Naperville clinic will serve as a key expansion center that will benefit from existing referral sources and marketing initiatives as current locations reach capacity.

At approximately 3,100 square feet, the clinic will offer ketamine treatments in addition to existing Wesana Clinics insurance reimbursable services such as general psychiatric care, Spravato, individual psychotherapy, neurocognitive testing and addiction medicine. The Naperville clinic will also look to showcase the evolution of the clinics through new value-added, insurance reimbursable services such as deep Transcranial Magnetic Stimulation (“dTMS”), group psychotherapy, cognitive training and other mental health and wellness care. The launch of the clinic is currently targeted for late Q1 2022.

“The Naperville expansion is a natural evolution for our clinics business and allows us to realize our vision of Wesana Clinics 2.0,” commented Daniel Carcillo, Chief Executive Officer of Wesana Health. “Serving as our flagship, we are positioned to help the Naperville community with much needed mental health access through new integrated and more effective personalized approaches to healing. Based on our research and understanding of our patient population, we are confident that the new clinic will be a validation of our view on the evolution of our clinics business into a more comprehensive care model.”

Leadership Changes

Israel Mirsky, Chief Marketing and Strategy Officer of Wesana, has transitioned out of the organization to pursue other opportunities. As an early executive of Wesana, Mr. Mirsky was instrumental in building out the Company’s marketing function and in refining the Company’s strategy. The Company would like to thank Mr. Mirsky for his contributions in the early stages of the company and for his role in building out one of Wesana’s key functions.

Hayim Raclaw, Chief Operating Officer of Wesana, has transitioned out of the organization to pursue other opportunities. As co-founder and CEO of PsyTech, Hayim led the development of the clinics and clinical software divisions that now comprise the Care Delivery segment of Wesana. The Company would like to thank Mr. Raclaw for a successful integration of PsyTech’s assets into Wesana and for his contributions to the combined organization.

“On behalf of the management team, I would like to thank Israel and Hayim for their commitment and contributions to building Wesana to its current stage and wish them all the best in their future endeavors,” commented Daniel Carcillo. “As our strategy continues to evolve on both sides of our business, these transitions serve as needed steps to realize our vision of helping patients transcend the barriers in mental health and performance.”

Additional Restructuring

The Company also announces a strategic restructuring program as part of the next phase of the business. The restructuring includes a reorganization and simplification of the Company’s operating structure and a reduction in the workforce. The restructuring program specifically looked to reduce layers of management, remove duplicative roles, and outsource certain non-core functions in order to streamline operations and drive efficiency. The overall restructuring program has reduced general corporate overhead annualized commitments by $1.1M excluding charges associated with severance and related costs.

“We are announcing extensive changes today to make Wesana a stronger, more durable and focused company,” said Zed Wang, Chief Financial Officer of Wesana. “This includes making the difficult decision to part ways with some of our workforce. Saying goodbye to teammates is not a decision that was taken lightly, and we remain very grateful to everyone for their hard work and dedication to Wesana. These changes better positioned our organization by allowing our organization to be laser focused on executional excellence, R&D, quality and accessibility of care.”

On behalf of the Board of Directors:

“Daniel Carcillo” Chief Executive Officer

About Wesana Health

Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and proprietary protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.

Investor Relations:

Keenan Gentry

Email: IR@wesanahealth.com 

Phone: 702.329.8038

Media Contacts:

Isadora Forman

Email: media@wesanahealth.com

Phone: 917.653.4613

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to: the initiation of Phase I clinical trials in late 2022, the launch of the Naperville clinic in late Q1 2022 and any other statement that may predict, forecast, indicate or imply future plans, intentions, levels of activity, results, financial position, operational or financial performance or achievements. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made.

Certain factors that influence successfully initiating Phase I clinical trials in late 2022 include: (i) the Company has retained industry leading experts/consultant to assist with strategy, drafting and submission of pre-IND/CTA meeting Packages; (ii) preparation of materials and internal discussions with consultants have been ongoing, productive and in line with timeline expectations; (iii) the Company has submitted an authorization letter to the FDA authorizing one of its Contact Research Organizations to communicate directly with the FDA on the Company’s behalf and personnel capable of attending the pre-IND/CTA meetings on behalf of the Company have been engaged; (iv) timelines for completion of pre-clinical studies and the receipt of a final report on the Anxiety and Depression Effects Study have been met; (v) the Company has identified the next key IND-enabling studies, including the pharmacology and toxicology assessments necessary to support submissions; (vi) the Company has substantially completed drafting the protocols for the above-referenced IND enabling studies, including the pharmacology and toxicology assessments; (vii) the pre-IND meeting is contemplated to provide the Company with the requisite guidance as to whether the protocols for the IND enabling studies are sufficient.

Certain assumptions that influence successfully initiating Phase I clinical trials in late 2022 include: (i) third parties assisting the Company with the pre-IND/CTA submissions will continue to satisfy deadlines on deliverables within anticipated timeframes; (ii) the pre-IND/CTA meetings are positive and support that a drug development plan and future clinical trials are going to be acceptable to the FDA and Health Canada; (iii) the Company and its consultants can efficiently and timely address any additional correspondence, submission of additional materials or information pursuant to any ongoing requests from FDA/Health Canada as they may arise during the course of their review following the filing of submissions; (iv) additional pre-clinical studies will be commenced and completed on a timely basis and results will be supportive and as anticipated; (v) the Company’s pre-clinical studies (animal pharmacology and toxicology testing) generate data and analyses to support an FDA decision that it is safe to proceed with human trials of the Company’s formulation; and (vi) the Company is able to maintain a GMP supply source necessary to conduct in-human clinical trials.

Certain factors that influence successfully launching the Naperville clinic in late Q1 2022 include: (i) the Company has identified a third clinic location and property and is finalizing the lease, (ii) should the Company procure additional capital and proceed with a lease in connection with the identified third property, renovations and permitting of the property for the purpose of clinic operations are expected to be minimal, and (iii) the Company has an internal team dedicated to identifying potential target clinics and locations and evaluating and addressing issues that may arise during due diligence of any potential targets.

Certain assumptions that influence successfully launching the Naperville clinic in late Q1 2022 include: (i) there are no significant delays in the buildout for the Naperville clinic early in Q1 2022, and (ii) there are no significant delays in renovation/permitting.

Furthermore, such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual performance, achievements, actions, events, results, or conditions of the Company to be materially different from any future performance, achievements, actions, events, results or conditions expressed or implied by such forward-looking information. Such factors include, among others: reliance on third parties to plan, conduct and monitor product research and development; failure to comply with health and data protection laws and regulations; violations of laws and regulations resulting in repercussions; regulatory or political change; maintaining and enhancing reputation and brand recognition; ability to protect intellectual property; requirements to share intellectual property with service providers; negative operating cash flow and going concern; the detrimental impact of future losses and negative cash flow from operations; unfavorable publicity or consumer perception; not achieving publicly announced milestones; psychedelic inspired drugs possibly never being approved as medicines; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; exposure to the fluctuation of foreign exchange rates; enforcement of judgments and effecting service of process on directors and officers; general economic, market and business conditions, and other risks factors including those found in the Company’s annual information form dated September 3, 2021 filed on the Company’s profile on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR.

Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.

Posted on

Core One Labs Now Also Working to Biosynthesize DMT and Receives License

Core One Labs Now Also Working to Biosynthesize DMT and Receives License

Vancouver, British Columbia, Canada – January 8, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that it has progressed its work on biosynthesizing N,N-Dimethyltryptamine (“DMT”) and has been approved by Health Canada to add N,N-Dimethyltryptamine (“DMT”) to the schedule of approved controlled substances under the existing licence granted by the Controlled Drugs and Substances Act (”CDSA”) Dealer’s Licence (the “Licence”) which allows its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) to research and produce biosynthetic psilocybin.

Furnished with its renewed licence in the second half of 2021, and having now received approval to add DMT to its licence coverage, the Company’s wholly-owned subsidiary Vocan Biotechnologies Inc. under its operating lab’s licence, has furthered its engineering and design optimization efforts for the proprietary manufacturing of API-grade DMT. The Company’s team of scientists at Vocan have been working diligently to expand a psychedelics production pipeline to include DMT. Initial indications of design and engineering suggest that using the same recombinant enzyme fermentation platform utilized to produce API-grade psilocybin, Vocan scientists will be able to replicate its biosynthesized psylocibin successes and announce ability to produce stereochemically sound biosynthesized DMT at scale.

The Company is confident that replication of historical research and development processes performed for its successful biosynthesis of psylocibin will allow for a more rapid turn around of its second biosynthesized psychedelic compound, DMT. Following similar processes of engineering and design may also increase probability of the Company’s filing of a patent for this second proprietary compound in the near term.

“Based on the significant progress we have made on biosythesizing psilocybin, DMT is the next compound we are working to biosynthesize. As we expect completion of the process for psilocybin in the upcoming days, we believe that we can fast track the process for DMT, as it uses the same steps to biosynthesize the compounds. Our team of leading scientists have done an amazing job in getting us to this stage and we are excited about the results we are seeing.” Stated Joel Shacker CEO of the Company.

ABOUT CORE ONE LABS INC.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.
Joel Shacker
Chief Executive Officer
FOR FURTHER INFORMATION:
Email: info@core1labs.com
Telephone: 1-866-347-5058

FOLLOW US:
Website: https://core1labs.com/
Twitter: https://twitter.com/Coreonelabs
Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/
LinkedIn: https://www.linkedin.com/company/core-one-labs
Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

Posted on

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

XPhyto Announces New Director of Business Development and Head of Diagnostic Research

Vancouver, Canada, and Uttenweiler, Germany (January 10, 2022) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products including for the detection of COVID-19.

Director of Business Development

Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial professional with over 25 years of experience in planning and building out effective salesforces, strategic realignment, production relocation, and project management, which makes him ideally suited to drive product sales.

In addition to extensive consulting roles, Mr. Spleiss held senior positions including Chief Financial Officer of Wörwag Pharma, a private German health and generic pharmaceutical company with over EUR 200 million in annual sales and 900 employees. He led the company’s strategic professionalization and internationalization of operations, optimization of supply chains and sales processes, and expansion into new European, Asian and Latin American healthcare markets.

Mr. Spleiss’ expertise in production and supply chain management, cost optimization, and sales force and distribution network creation will be invaluable to XPhyto’s commercial strategy and execution.

Head of Diagnostic Research

Dr. Heinrich Jehle has joined XPhyto as Head of Diagnostic Research. Dr. Jehle has over 20 years’ experience in the research and development of innovative medical screening tests and diagnostics. Previously, Dr. Jehle held senior roles in project management and research & development at leading European biotech and diagnostics companies.

More recently, Dr. Jehle co-founded 3a-diagnostics GmbH as managing director where he led the development of the first saliva activated “in-mouth” biosensor candidates to identify active pathogens in the saliva and built a portfolio of innovative diagnostics biosensor products. The enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care.

“Mr. Spleiss and Dr. Jehle are tremendous additions to the XPhyto team,” said Prof. Dr. Thomas Beckert. “Mr. Spleiss brings robust knowledge and experience in the development of product sales and economic optimization with a demonstratable track record of success. Dr. Jehle’s scientific expertise ensures the continued advancement and commercialization of innovative biosensor and diagnostic products, which is a key component of XPhyto’s short- and long-term success.”

XPhyto is pleased to have embarked on a recent process of rapid and transformative leadership change and organizational optimization.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Posted on

Levitee Labs Announces Medical Advisory Board

Levitee Labs Announces Medical Advisory Board

Levitee Labs Announces Medical Advisory Board

  • Newly appointed Medical Advisory Board brings decades of relevant experience in addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelic medicine to Levitee Labs
  • Team of respected experts and key opinion leaders to support Levitee Labs’ industry-leading integrative wellness model and mission to improve treatments for those suffering from mental health and addiction disorders
  • The formation of a Medical Advisory Board aligns with Levitee Labs signing agreements to acquire addiction focused clinics and pharmacies in Alberta and British Columbia

VANCOUVER, BC, CANADA, JANUARY 6th, 2022 /CNW/ – Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the “Company” or “Levitee”), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, today announces the formation of a Medical Advisory Board consisting of experts across a diverse group of fields, including addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelics. The assembly of these forward-thinking pioneers and health professionals is another milestone for Levitee Labs establishing itself as the leading national provider in comprehensive mental health and addiction treatments.

North Americans are faced with an ever-increasing crisis of mental health and addiction disorders that demand innovation to flatten and reverse the curve. Much like the United States, Canada suffered a 74% increase in opioid-related deaths over the course of the first six months of the COVID-19 pandemic1.

Today’s standard of care has numerous shortcomings, and to be effective, appropriate treatments must be readily available and address the additional health issues that come with addiction and mental health disorders.

Levitee Labs is deeply committed to provide specialized mental health support to those in need through a strategy that includes consolidating and optimizing clinics and pharmacies and developing new treatment options, including those leveraging active ingredients in psychedelics.

Levitee Labs methodically recruited each member of the new Medical Advisory Board for their individual expertise and cumulative synergies that will facilitate expeditious and efficient growth through connection to other thought leaders and major players in all relevant industries.

“I’d like to formally welcome each new Medical Advisor; we are honored to have you as part of our team,” commented Pouya Farmand, Chief Executive Officer at Levitee Labs. “Providing effective, easily accessible treatment options to the millions of people suffering from substance abuse disorder is the foundation of our strategy and I am confident in the contributions the Medical Advisory Board will make to meet all our goals by changing the existing paradigm. Our strategy is solid, and our team is unparalleled, a combination that points to a bright future where negative addiction stigmas are removed and instead of feeling hopeless, patients readily get the help and support they need to overcome their difficult disorders.”

The Levitee Labs Medical Advisory Board consists of:

Mark Tarnopolsky, MD, PhD, FRCP(C): Dr. Tarnopolsky is Professor of Pediatrics and holds an Endowed Chair in, and is Division Head of, Neuromuscular and Neurometabolic Diseases at McMaster University Children’s Hospital, Hamilton, Ontario. In addition to extensive research efforts into the diagnosis and therapeutic options for these disorders, he has published over 500 PubMed articles with an h-index of 130. Dr. Tarnopolsky brings business experience as the former co-founder and Chief Scientific Officer (CSO) for Life Science Nutritionals. Dr. Tanopolsky is currently the CSO for Cora Therapeutics and SofTabsand looking at opportunities for the fast active delivery of other bioactive compounds including psychedelics, and the founder, CEO and CSO of Exerkine (exerkine.com) and Stayabove Nutrition (stayabovenutrition.ca).

Noha ElSayed, B.Sc.Pharm, APA: Mrs. ElSayed earned her Bachelor of Science degree in Pharmacy and obtained her Additional Prescribing Authorities from The Alberta College of Pharmacists. She is an active member of several specialized health care networks. Mrs. ElSayed has a passion for mental health care, addiction treatment, custom compounding, and travel health, as well as diabetes and chronic disease management education. She prides herself on staying up-to-date with the latest pharmacy practices and procedures and is an expert in custom compounding techniques and knowledge, Hepatitis C, Ketamine, pharmacy operations and optimization, establishing new (greenfield) pharmacies, pharmacy supply chains, and dermatology.

Bakir Al Tikriti, MD M.B.ch.B CCFP PGC(PAIN): Dr. Al Tikriti is an addiction medicine and chronic pain management specialist. He deals with complex addiction and mental health cases and medical management for chronic pain complex patients. Dr. Al Tikriti obtained his certificate in chronic pain management at the University of Alberta. He is also certified by the College of Family Physicians of Canada and a licensed member of the General Medical Council of the United Kingdom.

Mohammed Mosli, MD, FRCPC, ISAM: Dr. Mosli is a multilingual Public Health and Preventive Medicine physician specialized in Addictions Health, health services improvement, health promotion, environmental public health, and health policy. He has spent the last five years as a Medical Officer of Canada’s largest province-wide, fully-integrated health system that serves over four million patients. Dr. Mosli served, or currently serves, as a director, educator, or senior level manager for an array of organizations, including those in provincial, institutional, and private segments. He is a valuable physician member of the Opioid Addictions Medicine team for Levitee Clinics™ and Levitee Pharmacies™ in Alberta. Dr. Mosli earned his FRCPC (Fellow of the Royal College of Physicians of Canada) degree from the University of Calgary in Public Health and Preventive Medicine. He earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) degree in the field of Medical Sciences from King Abdulaziz University in Saudi Arabia. Dr. Mosli holds professional certifications in the International Society of Addictions Medicine; Incident Command System (ICS) for healthcare; and Quality Improvement in healthcare. He currently holds and has previously held licenses by the College of Physicians and Surgeons of Alberta (CPSA)(2012-Present); Licentiate of the Medical Council of Canada (LMCC)(2014-Present); Saudi Commission for Health Specialties (SCHS) 2009-2014; and Fellow of the Royal College of Physicians of Canada (FRCPC) (issued June 2017).

Eding Mvilongo, MD: Dr Eding Mvilongo is an Anesthesiologist working in Montréal, Québec. After graduating from Laurentian University with a BSc (Hon) in Physics, she completed a Master of Science in Mechanical Engineering at Queen’s University before pursuing medical school at Université Laval in Québec City, Québec. She returned to her native Montréal for her residency in Anesthesiology at McGill University. After graduation, she continued with subspecialty training in Pediatric Anesthesiology at the University of British Columbia (BC Children’s Hospital). Dr Mvilongo is currently practicing at Hôpital Cité-de-la-Santé and is affiliated with Hôpital Sainte-Justine, a major Pediatric Center in Québec. She is also an affiliated clinical professor at the Faculty of Medicine, Department of Anesthesiology and Pain Control of the Université de Montréal. She is an active member in her department, supervising residents in training as well as participating in key committees and coordinating surgical activities of the hospital. Her main areas of interests are Regional Anesthesia and Pain Control, Neonatal Resuscitation and Medical Simulation.

Through the acquisition of clinics, pharmacies and leading technologies, Levitee Labs is re-imagining the treatment dynamic and taking a holistic approach to bridge the gaps in therapeutic programs today. In November, the Company signed a letter of intent (LOI) to acquire 51% of a compounding pharmacy in Calgary, Alberta, Canada that will be used as an initial base for the production and distribution of pharmaceutical products, which will include pain and depression management products, such as ketamine. The Company also signed an LOI to acquire 100% of the issued and outstanding shares in a company owning and operating a chain of specialty addiction pharmacies located throughout the lower mainland of British Columbia, Canada.

Levitee Labs also announces that Maigul Wickham, CPA will assume duties, effective immediately, as the Chief Financial Officer of the company in place of Mason Darabi.

  1. https://www.kflaph.ca/en/healthy-living/fentanyl.aspx

About Levitee Labs 

Levitee is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

The Company’s current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com.

Investor and Corporate Communications: 

ir@leviteelabs.com

Media Contact: 

media@leviteelabs.com

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee’s business plans and proposed products, and the benefits derived from mushroom-infused products; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee’s future growth potential; and Levitee’s objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management’s current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee’s limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee’s public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.

Posted on

Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line

Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line

Vernon, British Columbia, January 6, 2022 – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the successful soft launch of seven new adaptogenic mushroom products in the United States, and the upcoming launch of the product line in the Canadian market during the first quarter of 2022.

Doseology’s new medicinal mushroom products have successfully completed test marketing with overwhelmingly positive ratings and reviews. Being among the most comprehensive available on the market, they will help fill the growing demand for high-quality adaptogenic nutraceuticals. The new line employs adaptogenic blends to improve on the single-extract tinctures commonly available. Blends have a higher market value because of increased user benefits and development challenges. 

The proprietary formulations make extensive use of natural mushroom fruiting bodies, pairing adaptogenic botanicals with vitamins for increased efficacy.  Significant research has shown positive effects of adaptogens with respect to stress reduction, resistance to mental fatigue, and improved attention capacity. The Doseology line combines adaptogens such as ginger, turmeric, yerba mate, and several mushroom species, with proven functional mushrooms such as lion’s mane, reishi, shiitake, maitake, royal sun, turkey tail, and others. These blended formulations deliver enhanced health and wellness benefits over single-ingredient products.

The new product line addresses the functional mushroom market, projected to grow to US$572 billion globally by 2028 with a CAGR of 6.1 percent (Data Bridge Market Research). Products in the new Doseology line address different segments of the market, including mood and depression, attention and focus, sleep and recovery, and anxiety.

In preparation for the Canadian launch, Doseology has received six Natural Product Number (NPN) licenses from Health Canada. The Company is currently exploring Canadian distribution channels, which is planned to include Amazon.ca. With US$7.14 billion in net sales (Statista, 2020), Amazon.ca is by a wide margin Canada’s largest online retailer. The Company’s direct marketing focus will enable it to quickly reach consumers who can benefit most, provide an engaging customer experience, and establish long-term relationships to maximize revenue. 

Daniel Vice, Doseology CEO and Director, comments, “After many months of product development, testing, and regulatory approval, we are pleased to finally launch our products in the U.S. market, and soon in Canada. By incorporating the nutrient-dense fruiting bodies of functional mushrooms and natural health-promoting adaptogens, our products were designed to optimize the user experience which reflects our commitment to deliver high-quality, natural solutions to improve physical & mental health.”

A core element of the Company’s mission is developing and providing psychedelic treatments for restoring mental health. Once the regulatory framework has been established, Doseology’s product line will form the foundation for psilocybin-based therapeutics, creating an entirely new market and fulfilling the Company’s vision of better mental health and wellness for millions globally.

Doseology has completed its application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada), which would permit the production of psychedelic compounds including psilocybin and psilocin, and mark a significant milestone in achieving the Company’s vision.

These announced developments will give consumers better access to the healing power of medicinal mushrooms, and bring Doseology closer to delivering innovative wellness solutions and mental health therapies.

Learn more about Doseology’s medicinal mushroom product line at doseology.com.

On Behalf of the Board of Directors

Daniel Vice
Chief Executive Officer and Director
Doseology Sciences Inc.

About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:
Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements
This corporate update contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Novamind Unveils New Design Concept for Clinics

Novamind Unveils New Design Concept for Clinics

TORONTO, ON / January 5, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today unveiled its clinic design concept (the “Design Concept”) to accommodate the unique requirements of psychedelic-assisted psychotherapy. The Design Concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.

Inclusive and welcoming, the Design Concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:

  • Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
  • Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
  • Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
  • Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA

To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.

“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”

Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”

To see renderings of the Design Concept, click here.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

About DesignAgency
DesignAgency is an award-winning international design studio that draws on over two decades of expertise in interior design, architectural and landscape concepting, strategic branding, and visual communications. With studios in Toronto, Washington, D.C., Los Angeles and Barcelona, DesignAgency has developed a global reputation for creating exceptional environments that people experience fully and deeply. Key to our success is the strength of collaboration. Our talented design teams are informed by curiosity, international perspectives, and a drive for innovation. Working across hospitality, residential, commercial, and retail sectors, we work with our clients and with local and international artists, craftspeople, and suppliers to realize extraordinary experiences and lasting value.

Contact Information
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: ir@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

Optimi Health Provides Dealer License Update and Comments on Health Canada’s Amendments to the Special Access Program (SAP)

Optimi Health Provides Dealer License Update and Comments on Health Canada’s Amendments to the Special Access Program (SAP)

SAP amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis.

VANCOUVER, BC ( January 5, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report the successful completion of the Health Canada inspection on December 21, 2021. The Company is in close contact with the regulator and welcomes finalization of the process in the coming weeks. Additionally, Optimi commends Health Canada for taking an active leadership role in finding solutions for the ongoing Canadian mental health crisis including access to psilocybin for therapeutic purposes through the Special Access Program (SAP).

Background

In Canada, drugs are authorized for sale only once they have successfully gone through the drug review process, including evaluation of safety, effectiveness and quality. However, Health Canada’s SAP allows practitioners to request access to drugs that are not available in Canada for the emergency treatment of patients with serious or life-threatening conditions who have exhausted other treatment options. Due to regulatory changes made in 2013, restricted drugs have not been made available through the SAP.

Since then, clinical trials have been the only avenue by which the sale of a restricted drug could be authorized for patient treatment. While clinical trials remain the best mechanism to authorize the sale of drugs, there are barriers to patient participation including geography or lack of clinical trial recruitment.

Yet, there has been ongoing scientific research into the efficacy and safety of certain restricted drugs. In response, Health Canada has today announced a reversal of the regulatory changes made in 2013 to Part C of the Food and Drug Regulations and has restored potential access to restricted drugs through the SAP.

What the regulatory amendments mean for Canadians

The regulatory amendments will allow physicians to request patient access to psychoactive substances, like psilocybin and MDMA, for psychedelic-assisted therapy. Decisions will remain on a case-by-case basis and will be reserved for serious, treatment-resistant or life-threatening conditions. The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.

“Optimi acknowledges the Trudeau government, former Health Minister Patty Hajdu, current Health Minister, Jean-Yves Duclos, Minister of Mental Health and Addictions, Carolyn Bennett, and officials within Health Canada’s Legislative and Regulatory Affairs Department for giving the public an opportunity to consult on this important program,” notes Bill Ciprick, Optimi’s CEO. “We believe the amendments will bring much-needed relief and comfort to the hundreds of veterans, first-responders and Canadians who will immediately benefit from psychedelic psychotherapy to help with treatment-resistant depression that is considered serious and life-threatening by their physician.”

Our vision

Upon approval of the Dealer’s license, Optimi’s vision is to be the leader in providing safe supply and the highest-grade GMP certified psilocybin across Canada and the world. We agree with Health Canada there should be continued research to test the efficacy and safety of  psychedelic drugs. Our first clinical trial to determine the safe and effective standardized micro-dose of psilocybin for mental health including anxiety and depression is currently awaiting Health Canada approval. Earlier last year, Optimi received a Section 56 exemption for research purposes and this initial trial will be conducted at the Bloom Clinic, which is Calgary’s first psychedelic assisted therapy centre.

“Optimi is committed to the safety and efficacy of our product, and we look forward to supplying Canadian and global institutions with the highest-quality psilocybin in the market,” said Mr. Ciprick.

The Company also announces it has issued 50,000 common shares, at a deemed price of $0.465 per share, subject to a hold period expiring May 5, 2022, in consideration of services provided.

On Behalf of the Board of Directors,

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022.

A corporate presentation from James Lanthier, CEO of Mindset, will be available on-demand starting Monday, January 10th at 7:00 a.m. ET. To view, register here.

For more information about the conference, or to schedule a one-on-one meeting with Mindset’s management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at lk@hcwco.com, or KCSA Strategic Communications at MindSet@kcsa.com.

The Company also announces that it has engaged Emerging Markets Consulting, LLC (“EMC”) to provide investor/public relations services. Based in Orlando, Florida, with affiliates around the world, EMC is an international investor relations firm that brings decades of combined experience in the investor relations industry. EMC’s services are intended to help small and mid-sized public companies establish brand awareness and increase market share to its customer base while improving visibility to the institutional and retail investment community.

Under the terms of the agreement (the “Agreement”), EMC has agreed to provide a combination of content production and strategic digital media services over a 12-month term for a total payment USD $250,000. To the knowledge of the Company, neither EMC nor any of its principals have an ownership interest, directly or indirectly, in Mindset or its securities, and the Company has not granted EMC or its principals any right to acquire such interests. EMC is at arm’s length to Mindset and has no other relationship with Mindset, except pursuant to the Agreement.

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

Forward-Looking Information
This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma Recaps 2021 Milestones and Highlights

Mindset Pharma Recaps 2021 Milestones and Highlights

– Evolving Pipeline of Psychedelic Compounds Focused on Improved Efficacy and Safety

– Advancing MSP-1014 as First Lead Drug Clinical Candidate to IND-Enabling Studies

TORONTO, Dec. 30, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today provided a recap of its 2021 milestones and highlights.

“In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies,” said James Lanthier, CEO of Mindset. “As we enter 2022, we are excited to advance these novel therapies towards the clinic as we progress IND-enabling studies for our lead candidate, MSP-1014, and select additional candidates from our other families of compounds. 2021 was, however, just the beginning for Mindset; we are building the industry’s leading drug discovery platform and intend to continue to break new ground in psychedelic drug discovery in order to bring patented, safe and effective therapies to those suffering from a range of mental illnesses and neurological disorders.”

Operational Highlights:

  • Expanded Patent Portfolio: Filed four provisional patent applications bringing the total to eight provisional applications filed to-date. Mindset also has filed four final PCT applications, which cover a broad range of novel, next generation drugs inspired by psilocybin, DMT, & 5-MeO-DMT and a novel psilocybin synthesis and manufacturing method.
  • Advanced First Lead Drug Candidate Toward Clinical Trials: Selected its first lead clinical candidate, MSP-1014, a differentiated psilocybin-based analog, to move forward into investigational new drug (IND)-enabling studies.
  • Growing Library of Novel Compounds: Synthesized over 100 novel compounds in more than 500 in vitro and in vivo studies.
  • Developed First-in-Class Benchmarking: Under the Cooperative Psychedelics Evaluation Platform (“COPE”) program, Mindset and its partner, InterVivo Solutions, continued to develop first-in-class benchmarking data across first-generation psychedelic drugs.
  • Effect Size & Safety Differentiation Driven by Technology Platform: Preclinical data generated across the four families of novel chemical entities resulted in the identification of a platform technology that enhances effect size and improves safety profiles of psychedelic drugs. A provisional patent application was filed in May of 2021.
  • Enhanced Leadership and Advisory Teams: Appointed Dr. Malik Slassi as Senior Vice President of Innovation, Mr. Ian Dean as Director of Preclinical Development, and Drs. Michael Rogawski, Guy Higgins, Joseph Gabriele and Ishrat Husain to its Scientific Advisory Board (SAB).

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.